FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:1245 October 23, 1997 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Ticlopidine hydrochloride (Ticlid) is a potent platelet-antiaggregating agent that has been used in the United States since 1991 to reduce the risk of thrombotic stroke in patients with aspirin intolerance. Recently, it has been demonstrated to decrease the incidence of cardiac events and reocclusion after the placement of a coronary-artery stent.¹ We report two cases of fulminant thrombotic thrombocytopenic purpura that developed within three weeks of the initiation of ticlopidine therapy after coronary-stent placement.

A 47-year-old woman presented in September 1996 with a 48-hour history of increasing confusion, icterus, and nausea. Three weeks before admission she had . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Smith, S. C. Jr, Dove, J. T., Jacobs, A. K., Ward Kennedy, J., Kereiakes, D., Kern, M. J., Kuntz, R. E., Popma, J. J., Schaff, H. V., Williams, D. O., Gibbons, R. J., Alpert, J. P., Eagle, K. A., Faxon, D. P., Fuster, V., Gardner, T. J., Gregoratos, G., Russell, R. O., Smith, S. C. Jr (2001). ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 37: 2239-2239 [Full Text]  
• Popma, J. J., Ohman, E. M., Weitz, J., Lincoff, A. M., Harrington, R. A., Berger, P. (2001). Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention. Chest 119: 321S-336S [Full Text]  
• (2000). The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 21: 2033-2041 [Abstract]  
• Paradiso-Hardy, F. L., Angelo, C. M., Lanctot, K. L., Cohen, E. A. (2000). Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality. CMAJ 163: 1441-1448 [Abstract] [Full Text]  
• Moy, B., Wang, J. C., Raffel, G. D., Marcoux II, J. P. (2000). Hemolytic Uremic Syndrome Associated With Clopidogrel: A Case Report. Arch Intern Med 160: 1370-1372 [Abstract] [Full Text]  
• Gras, E., Matias-Guiu, X., Catasus, L., Arguelles, R., Cardona, D., Prat, J. (2000). Application of microsatellite PCR techniques in the identification of mixed up tissue specimens in surgical pathology. J. Clin. Pathol. 53: 238-240 [Abstract] [Full Text]  
• Sheffield, J. V.L., Merrens, E., Kupfer, Y., Tessler, S. (1998). More about Thrombotic Thrombocytopenic Purpura. NEJM 338: 548-548 [Full Text]